Many natural products likewise show promise for OA treatment, especially regarding ferroptosis in chondrocytes
If DefenCath TM receives FDA marketing authorization before July 1, 2023, the new technology add-on payment for cases involving the use of this technology would be made effective for ( discharges beginning in the first quarter after FDA marketing authorization is granted
Also, most mechanistic, epigenetic, endocrine, and microbiome studies to date have been conducted in high-income settings, while studies from LMICs are more observational or epidemiologic, limiting the generalizability of findings
It is not intended for human consumption, injection, therapeutic use, or diagnostic procedures